Lexaria (NASDAQ: LEXX) Demonstrates DehydraTECH(TM)-Liraglutide Performance with GLP-1 Diabetes Animal Study

September 18, 2024 10:14:50
  • Lexaria, a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study
  • The study was made up of three main groups of formulations: DehydraTECH-processed CBD; semaglutide (including “Rybelsus(R)”) and liraglutide
  • The DehydraTECH-CBD and DehydraTECH-liraglutide both outperformed Rybelsus(R), which was a surprise outcome. DehydraTECH-liraglutide posted a weight reduction of 4.74%, the most significant in the study
  • For Lexaria, this continued outperformance of DehydraTECH-liraglutide is of particular interest, particularly since many third-party studies have shown semaglutide to be more than twice as effective as liraglutide in promoting weight loss
  • As the study progresses, Lexaria’s management is optimistic that it will realize positive and ground-breaking results that will demonstrate the superiority and potential of its technology

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study. This study explores Lexaria’s patented technology, DehydraTECH(TM), and its potential in addressing diabetes and weight loss. More importantly, it looks to establish whether DehdyraTECH processing results in higher brain absorption than non-DehydraTECH arms, with a focus on glucagon-like peptide 1 (“GLP-1”) drugs, liraglutide and semaglutide (https://cnw.fm/iAhxm).

This part of the study was comprised of eight different formulation arms. Arms A through D used different DehydraTECH-CBD compositions, with arms E and F using DehydratTECH-processed Rybelsus, and arms G and H using pure GLP-1 drugs (semaglutide and liraglutide, respectively) processed with…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

CBDWire
Denver, CO
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is powered by IBN